BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Campo I, Zorzetto M, Bonella F. Facts and promises on lung biomarkers in interstitial lung diseases. Expert Review of Respiratory Medicine 2015;9:437-57. [DOI: 10.1586/17476348.2015.1062367] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Bonella F, Campo I, Zorzetto M, Boerner E, Ohshimo S, Theegarten D, Taube C, Costabel U. Potential clinical utility of MUC5B und TOLLIP single nucleotide polymorphisms (SNPs) in the management of patients with IPF. Orphanet J Rare Dis 2021;16:111. [PMID: 33639995 DOI: 10.1186/s13023-021-01750-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
2 Bergantini L, d'Alessandro M, Vietri L, Rana GD, Cameli P, Acerra S, Sestini P, Bargagli E. Utility of serological biomarker' panels for diagnostic accuracy of interstitial lung diseases. Immunol Res 2020;68:414-21. [PMID: 33089426 DOI: 10.1007/s12026-020-09158-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
3 Cameli P, Bargagli E, Bergantini L, d'Alessandro M, Pieroni M, Fontana GA, Sestini P, Refini RM. Extended Exhaled Nitric Oxide Analysis in Interstitial Lung Diseases: A Systematic Review. Int J Mol Sci 2020;21:E6187. [PMID: 32867116 DOI: 10.3390/ijms21176187] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
4 Inoue Y, Kaner RJ, Guiot J, Maher TM, Tomassetti S, Moiseev S, Kuwana M, Brown KK. Diagnostic and Prognostic Biomarkers for Chronic Fibrosing Interstitial Lung Diseases With a Progressive Phenotype. Chest 2020;158:646-59. [PMID: 32268131 DOI: 10.1016/j.chest.2020.03.037] [Cited by in Crossref: 24] [Cited by in F6Publishing: 33] [Article Influence: 12.0] [Reference Citation Analysis]
5 Hirano C, Ohshimo S, Horimasu Y, Iwamoto H, Fujitaka K, Hamada H, Kohno N, Komoto D, Awai K, Shime N, Bonella F, Guzman J, Kühl H, Costabel U, Hattori N. Baseline High-Resolution CT Findings Predict Acute Exacerbation of Idiopathic Pulmonary Fibrosis: German and Japanese Cohort Study. J Clin Med 2019;8:E2069. [PMID: 31771313 DOI: 10.3390/jcm8122069] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
6 Mccarthy C, Kokosi M, Bonella F. Shaping the future of an ultra-rare disease: unmet needs in the diagnosis and treatment of pulmonary alveolar proteinosis. Current Opinion in Pulmonary Medicine 2019;25:450-8. [DOI: 10.1097/mcp.0000000000000601] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
7 Mishra S, Shah MI, Sarkar M, Asati N, Rout C. ILDgenDB: integrated genetic knowledge resource for interstitial lung diseases (ILDs). Database (Oxford) 2018;2018. [PMID: 29897484 DOI: 10.1093/database/bay053] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Meyer KC. Pulmonary fibrosis, part II: state-of-the-art patient management. Expert Rev Respir Med 2017;11:361-76. [PMID: 28345369 DOI: 10.1080/17476348.2017.1312347] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
9 Bonella F, Stowasser S, Wollin L. Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib. Drug Des Devel Ther 2015;9:6407-19. [PMID: 26715838 DOI: 10.2147/DDDT.S76648] [Cited by in Crossref: 12] [Cited by in F6Publishing: 25] [Article Influence: 1.7] [Reference Citation Analysis]